A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age)
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 入组人数
- 159
- 试验地点
- 48
- 主要终点
- Number of Participants with Abnormalities in Clinical Laboratory Parameters
研究概览
简要总结
The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have completed the dosing planned in the primary pediatric ustekinumab study
- •Benefit of continued ustekinumab therapy (that is, a clinical response or clinical remission as defined in the primary study at the final efficacy visit of the primary study)
- •Parent(s) (preferably both if available or as per local requirements), legal guardian(s) or their legally acceptable representative must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to allow the child to participate in the study. Assent is also required of children capable of understanding the nature of the study (typically 7 years of age and older) as described in Informed Consent Process. An adolescent who signs the assent form will be given the opportunity to sign an adult ICF at a later visit when they reach the age of majority during the study to indicate that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
- •Must be willing and able to adhere to the lifestyle restrictions specified in this protocol
- •Females of childbearing potential must have a negative urine pregnancy test at enrollment and prior to study intervention administration
排除标准
- •Are pregnant, nursing, or planning pregnancy or fathering a child
- •Have had any of (a) confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2 [COVID-19]) infection (test positive), or (b) suspected SARS-CoV-2 infection (clinical features without documented test results), or (c) close contact with a person with known or suspected SARS-CoV-2 infection: Exception: (i) may be included with a documented negative result for a validated SARS-CoV-2 test: obtained at least 2 weeks after conditions (a), (b), (c) above (timed from resolution of key clinical features if present, example, fever, cough, dyspnea) and (ii) with absence of all conditions (a), (b), (c) above during the period between the negative test result and the baseline study visit
- •Taken any disallowed therapies as noted in the primary study, before the planned first long-term extension (LTE) dose of study intervention
- •Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (example, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
- •Participants who receive a live vaccination may be permitted to remain in the study, if approved by the sponsor and study intervention is held for a period of time specified by the sponsor. Receipt of a live severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) vaccine (against the virus that causes Coronavirus Disease 2019 [COVID-19]) is not automatically an exclusion criterion and must be discussed with the medical monitor
研究组 & 干预措施
Ustekinumab
Participants will have continued access to ustekinumab for primary study (CNTO1275CRD1001, CNTO1275PUC3001, CNTO1275CRD3004, CNTO1275JPA3001) participants who in the opinion of the investigator will continue to benefit from ustekinumab therapy. All blinded participants who enroll in the long-term extension (LTE) from blinded primary studies with both every 8 weeks (q8w) and every 12 weeks (q12w) dosing groups just prior to the end of the primary study will be assigned to the q8w dosing regimen. Participants enrolling in the LTE from an unblinded primary study will remain on the final dosing regimen that they were receiving in the primary study. Participants enrolling from the Exposure Optimization Substudy may be eligible to remain on the every 4 weeks (q4w) dosing regimen.
干预措施: Ustekinumab (Drug)
结局指标
主要结局
Number of Participants with Abnormalities in Clinical Laboratory Parameters
时间窗: Up to 6 years and 4 months
Number of participants with abnormalities in clinical laboratory parameters (such as hematology and serum chemistry) will be reported.
Number of Participants With Adverse Events (AEs)
时间窗: Up to 6 years and 4 months
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.
Number of Participants with AEs Leading to Discontinuation of Study Intervention
时间窗: Up to 6 years and 4 months
Number of participants with AEs leading to discontinuation of study intervention will be reported.
Number of Participants with Injection-site Reactions
时间窗: Up to 6 years and 4 months
Number of participants with injection-site reactions will be reported. An injection-site reaction is any adverse reaction at a subcutaneous (SC) study intervention injection-site.
Number of Participants With AEs of Worsening of the Disease
时间窗: Up to 6 years and 4 months
Number of participants with AEs of worsening of the disease will be reported.
Number of Participants With Serious Adverse Events (SAEs)
时间窗: Up to 6 years and 4 months
A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Number of Participants with AEs of Interest
时间窗: Up to 6 years and 4 months
Number of participants with AEs of special interest (any newly identified malignancy case of active tuberculosis \[TB\], or opportunistic infection occurring after the first administration of study intervention\[s\]) will be reported.
Number of Participants With Concomitant Therapy due to Loss of Response
时间窗: Up to 6 years and 4 months
Number of participants with concomitant therapy due to loss of response will be reported.
次要结局
未报告次要终点